Jump to content



LLS-Funded Investigators to Share Research at Upcoming Symposium

Posted by lynnesmith in The LLS Blog, 28 August 2014 · 74 views
Leukemia & Lymphoma Society, LLS and 2 more...

Many researchers funded by The Leukemia & Lymphoma Society (LLS) will be sharing their work at a blood cancer symposium hosted by the American Association for Cancer Research on September 20-23 in Philadelphia.

The conference, "Hematologic Malignancies: Translating Discoveries to Novel Therapies," focuses on developments in the research and treatment of blood cancers. Presentations will range from basic science discoveries to their translation in the clinic, and will cover scientific areas that cut across all blood cancers.

The following are among the LLS-funded researchers who will be presenting:

Myeloma and Acute Myeloid Leukemia. Irene Ghobrial, M.D., Dana-Farber Cancer Institute, leads a team looking at ways to prevent the precursors to these diseases from progressing to more lethal blood cancers.

Immunotherapy. Carl June, M.D., University of Pennsylvania, is advancing an immunotherapy using engineered T-cells, and Ronald Levy, M.D., Stanford University, is developing a vaccine for mantle cell lymphoma.

Epigenetics. Catherine Wu, M.D., is studying the biology of genetic and epigenetic heterogeneity and impact on outcome in chronic lymphocytic leukemia (CLL); Jonathan Licht, M.D., leads a SCOR team studying how mutant epigenetic proteins cause blood cancers; Ari Melnick, M.D., Weill Cornell Medical College, focuses on how the epigenetic process is disrupted in cancers; and James Bradner, Dana-Farber, is targeting the very difficult to drug MYC oncogene by inhibiting another class of molecules called BET proteins.

Drug Resistance. Adolfo Ferrando, M.D., Columbia University, is looking at patients with peripheral T-cell lymphoma and acute lymphoblastic leukemia and Anthony Letai, M.D., Ph.D., Dana-Farber, studies why chemotherapy works in some patients with acute myeloid leukemia (AML) and not in others.

Diffuse Large B-Cell Lymphoma. Margaret Shipp, M.D., Dana Farber, is studying deficiency of gene p53, a known tumor suppressor.

Genomic Profiling. Charles Mullighan, M.D., St. Jude’s Children’s Research Hospital, is focused on the genetic mutations that make certain pediatric acute lymphoblastic leukemia patients more resistant to treatment.

  • 1 Total Blogs
  • 389 Total Entries
  • 281 Total Comments
  • The LLS Blog Latest Blog
  • admin Latest Blogger

47 user(s) are online (in the past 15 minutes)

0 members, 38 guests, 0 anonymous users

Bing (6), Google (3)